Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions

The Cigna Group (NYSE: CI ) stock is lower on Thursday after the company reported second-quarter earnings results.

Q2 Earnings And Revenue Beat Expectations The health plan company reported second-quarter 2026 adjusted earnings of $7.78 per share, beating the consensus of $7.60 per share.

Adjusted revenue rose 7% to $71.558 billion, beating the consensus of $70.339 billion, primarily driven by Evernorth Health Services and Cigna Healthcare.

Read Also: FTC Says CVS Caremark Settlement Could Save Consumers Upto $13 Billion Customer Relationships Decline As Pharmacy Membership Falls Total customer relationships decreased 3% from December 31, 2025 to 182.8 million.

Pharmacy customers decreased 4% from December 31, 2025 to 118.2 million, reflecting expected client transitions and lower membership from health plan clients.

Medical customers increased 2% from December 31, 2025 to 18.4 million, reflecting growth in Middle and Select markets, partially offset by lower membership in National Accounts.

Evernorth Health Services adjusted revenues increased 6% to $61.468 billion.

Within Evernorth, Pharmacy Benefit Services revenue rose 8% to $34.496 billion, while Specialty and Care Services revenue increased 4% to $26.972 billion.

Specialty and Care sales were $26.972 billion, increased 4%, reflecting strong specialty volume growth.

Healthcare segment sales increased 9% to $11.728 billion, primarily reflecting premium rate increases to cover expected increases in medical costs.

Medical Care Ratio Increases Medical care ratio (MCR) was 84.5% for the second quarter of 2026, compared to 83.2% a year ago, primarily reflecting higher prior-year risk adjustment benefits within the Individual and Family Plans business recognized in the second quarter of 2025.

Ann Dennison, Cigna EVP and CFO, in an earnings conference call, said, “In the second quarter we observed moderating GLP-1 growth as coverage levels slightly declined and utilization growth trended down from elevated levels experienced in prior periods.

We expect this trend to continue throughout the remainder of the year, and it is contemplated in our full-year outlook.” “By harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day.

Our strong second quarter results reflect continued progress against these priorities and demonstrate the effectiveness of our strategy and execution,” said Brian Evanko, President and CEO of Cigna Group.

2026 Outlook Cigna expects fiscal 2026 adjusted earnings of at least $30.45 compared to the consensus of $30.41 and prior guidance of at least $30.35 per share.

The company said the outlook reflects the strong first-half performance while maintaining a prudent view of the current environment.

Cigna Healthcare affirmed its Medical Care Ratio guidance to be between 83.7% and 84.7%.

CI Price Action: Cigna Group shares were down 2.05% at $290.39 at the time of publication on Thursday, according to Pro data.

Read Also: 'All Bark and No Bite': Peter Schiff Says Kevin Warsh Chose Inflation Photo: Shutterstock